全文获取类型
收费全文 | 27520篇 |
免费 | 1676篇 |
国内免费 | 80篇 |
专业分类
耳鼻咽喉 | 196篇 |
儿科学 | 874篇 |
妇产科学 | 619篇 |
基础医学 | 4033篇 |
口腔科学 | 491篇 |
临床医学 | 4454篇 |
内科学 | 4708篇 |
皮肤病学 | 457篇 |
神经病学 | 2706篇 |
特种医学 | 633篇 |
外科学 | 2107篇 |
综合类 | 173篇 |
一般理论 | 26篇 |
预防医学 | 3298篇 |
眼科学 | 782篇 |
药学 | 1871篇 |
1篇 | |
中国医学 | 56篇 |
肿瘤学 | 1791篇 |
出版年
2023年 | 193篇 |
2022年 | 372篇 |
2021年 | 711篇 |
2020年 | 467篇 |
2019年 | 635篇 |
2018年 | 772篇 |
2017年 | 549篇 |
2016年 | 618篇 |
2015年 | 804篇 |
2014年 | 1224篇 |
2013年 | 1607篇 |
2012年 | 2089篇 |
2011年 | 2342篇 |
2010年 | 1560篇 |
2009年 | 1551篇 |
2008年 | 1773篇 |
2007年 | 1828篇 |
2006年 | 1776篇 |
2005年 | 1664篇 |
2004年 | 1597篇 |
2003年 | 1480篇 |
2002年 | 1284篇 |
2001年 | 165篇 |
2000年 | 126篇 |
1999年 | 170篇 |
1998年 | 220篇 |
1997年 | 168篇 |
1996年 | 161篇 |
1995年 | 116篇 |
1994年 | 125篇 |
1993年 | 106篇 |
1992年 | 72篇 |
1991年 | 87篇 |
1990年 | 71篇 |
1989年 | 78篇 |
1988年 | 47篇 |
1987年 | 47篇 |
1986年 | 47篇 |
1985年 | 49篇 |
1984年 | 67篇 |
1983年 | 72篇 |
1982年 | 70篇 |
1981年 | 48篇 |
1980年 | 50篇 |
1979年 | 34篇 |
1978年 | 22篇 |
1977年 | 25篇 |
1976年 | 24篇 |
1975年 | 19篇 |
1974年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Sandra E. File 《Human psychopharmacology》1987,2(3):151-158
The clinical efficacy of the benzodiazepines in reducing anxiety is widely accepted. However, the search for novel anxiolytics continues, motivated by the hope of finding a non-sedative anxiolytic. This article reviews the pre-clinical evidence for new compounds as it relates both to their anxiolytic actions in animal tests and to their sedative potential. Drugs acting at sites on the GABA-benzodiazepine receptor complex are discussed, as well as the potential importance of aminergic and peptidergic pathways. 相似文献
42.
Sandra V Navarra 《Nephrology, dialysis, transplantation》2006,21(3):579-581
Systemic lupus erythematosus (SLE) is a complex disease whichhas posed a continuing challenge to scientists and cliniciansof diverse areas of specialization. It serves as a model forthe study of the mechanisms of autoimmunityprovidingan important basis for the development of novel targeted therapiesin lupus and related conditions. The pathophysiology of SLE stems from the abnormal clearanceof apoptotic cells and/or endothelial activation. Material fromdying cells such as apoptotic blebs that are not efficientlyremoved may act as antigenic stimuli and lead to the developmentof autoantibodies with consequent formation of immune complexesand an inflammatory response in a variety of organ systems [1].This 相似文献
43.
44.
Dr. Sandra S. Garner Pharm.D. Dr. Donald B. Wiest Pharm.D. Mr. J. Warren Bradley R.R.T. 《Pharmacotherapy》1994,14(2):210-214
Study Objective . To determine albuterol delivery by metered-dose inhaler (MDI) in an in vitro pediatric mechanical ventilatory circuit model. The influence of a spacing device, endotracheal tube (ETT) diameter and length, and air humidity was also investigated. Design . An albuterol MDI canister was connected to an AeroVent spacer or Airlife MDI adapter and ETT 4.0, 5.0, or 6.0 mm at commercially available and equal lengths. The ETT tip was attached to an in-line filter holder with a 1-μm type A/E glass fiber filter. Ventilator settings were fractional concentration of inspired oxygen 50%, tidal volume 250 ml, inspiratory:expiratory (I:E) ratio 1:3, rate 25 breaths/minute, temperature 35°C, and a decelerating flow pattern. Ten albuterol canisters were activated two times each (total 2000 μg) into dry (4.0-, 5.0-, and 6.0-mm ETT) and humidified air (4.0- and 6.0-mm ETT) and repeated in triplicate. Percentage MDI output was determined by weighing the filter before and after drug administration (balance sensitivity 10 μg). Significant differences (p≤0.05) among the groups with and without a spacer and in dry and humidified air were determined by ANOVA with Scheffe's multiple comparison test. Multiple regression was used to determine significant associations between ETT diameter and length and delivery. Main Results . With the AeroVent spacer in humidified air, delivery with the 4.0- and 6.0-mm ETT was approximately 2.3% and 5%, respectively. The spacer and dry air significantly improved delivery. Conclusions . In humidified air, the dose of albuterol by MDI with an AeroVent spacer should be doubled for children intubated with 6.0-mm ETT, and four puffs administered for every one puff desired for 4.0-mm ETT. The results of this investigation should prove useful in initial clinical trials of albuterol MDI in ventilator-dependent infants and children. 相似文献
45.
Sandra E. File Helio Zangrossi Jr Fiona L. Sanders Peter S. Mabbutt 《Psychopharmacology》1994,113(3-4):543-546
Rats given one or two 5-min trials in the elevated plus-maze had plasma corticosterone concentrations significantly higher than the home cage control group and there was no sign of habituation in the group given two trials. In rats given two plus-maze trials the corticosterone responses were significantly higher in the group given 10-min rather than 5-min trials. A previous experience of cat odour (1 week earlier) has no effect on the plasma corticosterone response, but did have an anxiogenic effect that could be detected by a decrease in the percentage of time spent on the open arms of the plus-maze. The results are discussed with reference to the nature of anxiety generated by trials 1 and 2 and by the trial duration in the plus-maze, and with respect to dissociation between behavioural and endocrinological measures. 相似文献
46.
Anita MacDonald Dr Sandra Warrington Chairman Professional Development Committee 《Journal of human nutrition and dietetics》1990,3(2):71-77
At the present time, there are many fundamental issues coming from the Department of Health or from other national organizations, which will have an effect on the future development of the dietetic profession. The British Diatetic Association (BDA) Professional Development Committee will consider these issues, as and when appropriate, and will publish the information in the form of Briefing Papers.
The first Briefing Paper on 'Quality Assurance' was published by the BDA in November 1989. The second on 'Measuring clinical outcome' is published below. In each case the opinion of BDA members and specialist groups has been sought and the Professional Development Committee wishes to thank individuals and the specialist groups for their comments.
The Briefing Papers are intended to provide information and promote discussion among the membership. I would welcome further comments from readers, which may be directed to the British Dietetic Association Office. 相似文献
The first Briefing Paper on 'Quality Assurance' was published by the BDA in November 1989. The second on 'Measuring clinical outcome' is published below. In each case the opinion of BDA members and specialist groups has been sought and the Professional Development Committee wishes to thank individuals and the specialist groups for their comments.
The Briefing Papers are intended to provide information and promote discussion among the membership. I would welcome further comments from readers, which may be directed to the British Dietetic Association Office. 相似文献
47.
48.
Milton J. Guiberteau MD Pamela A. Wilcox RN MBA Sandra Bjork RN JD 《Journal of the American College of Radiology》2004,1(2):92-97
Clinical practice guidelines have emerged as a reality for medical practitioners over the past 20 years. Although virtually all groups interested in the development of practice guidelines hope for improvements in patient care, secondary expectations vary widely among those using them. Their use in daily practice by physicians has met with resistance from barriers including concerns of “cookbook” medicine, a loss of autonomy, and increased professional liability. The recent experience of the ACR in addressing these challenges illustrates that physicians are receptive to steps perceived to mitigate the risks accompanying the use of guidelines as well as to efforts to increase their understanding of implementing guidelines in clinical practice. The experiences of other medical societies and an inventory of future trends reveal additional challenges associated with the use of practice guidelines, as third parties look to guidelines as points of reference for gauging the performance of health care providers. 相似文献
49.
50.
Erika W. Wamsteker Author Vitae Rinie GeenenAuthor Vitae Pierre M.J. ZelissenAuthor Vitae Eric F. van FurthAuthor Vitae Jolein IestraAuthor Vitae 《Journal of the American Dietetic Association》2009,109(11):1903-1908
Unrealistic weight-loss goals may impede the success of weight-loss attempts. The aim of this study was to examine the frequency of unrealistic goals and their association with other patient characteristics at the start of a weight-loss program. For patients with a body mass index (calculated as kg/m2) of 30 to 35, 35 to 40, or 40 to 50, medically advised weight-loss goals were set at 10%, 15%, and 20% of current weight, respectively. Personal weight-loss goals exceeding the medically advised goal by >50% were considered unrealistic. Obesity-related beliefs were measured by the “Obesity Cognition Questionnaire” and the eating-behavior self-efficacy scale of the “Obesity Psychosocial State Questionnaire.” From September 2003 until March 2006, 90 patients were enrolled in the study, 26 men and 64 women, with a mean age of 43 years (range=18 to 68 years) and body mass indexes ranging from 30 to 50. Unrealistic goals were observed in 49% of the patients and were more frequent in younger patients (P=0.03), in patients attributing their obesity to physical causes (r=0.35, P=0.001), and in patients not attributing their obesity to behavioral causes (r=−0.28, P=0.008). This study confirms that discrepancies in weight-loss goals between obese patients and professionals occur frequently. Because unrealistic goals can hamper long-term outcomes of weight-loss programs, better outcomes could possibly be achieved by addressing unrealistic weight-loss goals before treatment. 相似文献